PF-05231023

PF-05231023 is a long-acting fibroblast growth factor 21 (FGF21) analog and is an FGF21-receptor agonist. It is also suitable for development as a potential treatment for T2DM. PF-05231023 is a analog of long-acting fibroblast growth factor 21.PF-05231023 suppresses oxidative-stress-induced inflammation in photoreceptors. PF-05231023 decreases the variability of retinal NRF2 levels and displays a trend (non-significant) towards increased NRF2 levels in Akita mice. PF-05231023 decreases retinal IL-1β mRNA expression in Akita mice. PF-05231023 enhances cone-specific arrestin4 expression in Akita mice. PF-05231023 restores photoreceptor morphology in Akita mice. Administration of native FGF21 and PF-05231023 (3 mg/kg or 10 mg/kg; subcutaneously twice a week for two weeks) improves glucose tolerance and liver insulin sensitivity in Zucker rats. PF-05231023 (10 mg/kg; intraperitoneally injected) reduces retinal inflammation in diabetic mice. (In Vivo) :Animal Model: Eight week old Zucker ratsDosage: 3 mg/kg and 10 mg/kg.Administration: Subcutaneously twice a week for two weeks.Result: There was no change of BW observed, and food intake was not changed in the treated groups compared to control. Caused a significant decrease of glucose excursion during the oral glucose tolerance test (OGTT) compared to control.